Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] Company Overview - Upstream Bio is developing verekitug, a monoclonal antibody that targets the receptor for thymic stromal lymphopoietin (TSLP), which is a key driver of inflammatory responses [2] - Verekitug is currently in separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [2] - The company aims to address significant unmet medical needs for patients who are underserved by existing treatments [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in investor conferences in March 2026, including: - TD Cowen 46 Annual Health Care Conference on March 4, 2026, at 9:50 a.m. ET [3] - 2026 Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET [3] - Live webcasts of these presentations will be available on Upstream Bio's website [1]
Upstream Bio to Participate in Upcoming March Investor Conferences